Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Early Phase 1:1
Not Applicable:1
Drug Approvals
2
FDA:2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (50.0%)Not Applicable
1 (50.0%)Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)
Not Applicable
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- BAMF Health
- Target Recruit Count
- 30
- Registration Number
- NCT05823402
- Locations
- 🇺🇸
BAMF Health, Grand Rapids, Michigan, United States
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
Early Phase 1
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- BAMF Health
- Target Recruit Count
- 100
- Registration Number
- NCT05558956
- Locations
- 🇺🇸
BAMF Health, Grand Rapids, Michigan, United States
News
PSMA PET Imaging Transforms Prostate Cancer Management with Multiple FDA-Approved Agents
PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18.